219,460 Shares in Revolution Medicines, Inc. $RVMD Purchased by Marsico Capital Management LLC

Marsico Capital Management LLC purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 219,460 shares of the company’s stock, valued at approximately $17,480,000.

Several other hedge funds have also recently modified their holdings of the stock. Swiss National Bank raised its position in shares of Revolution Medicines by 2.0% during the 4th quarter. Swiss National Bank now owns 276,331 shares of the company’s stock worth $22,010,000 after purchasing an additional 5,500 shares during the last quarter. Nuveen LLC raised its position in shares of Revolution Medicines by 20.4% during the 4th quarter. Nuveen LLC now owns 406,241 shares of the company’s stock worth $32,357,000 after purchasing an additional 68,767 shares during the last quarter. Xponance LLC raised its position in shares of Revolution Medicines by 3.6% during the 4th quarter. Xponance LLC now owns 8,826 shares of the company’s stock worth $703,000 after purchasing an additional 307 shares during the last quarter. Empowered Funds LLC acquired a new stake in Revolution Medicines in the 4th quarter valued at about $77,000. Finally, Meeder Advisory Services Inc. acquired a new stake in Revolution Medicines in the 4th quarter valued at about $319,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Stock Performance

NASDAQ:RVMD opened at $149.23 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80. The stock has a market capitalization of $31.73 billion, a P/E ratio of -21.11 and a beta of 1.40. The company has a 50 day moving average price of $139.66 and a 200 day moving average price of $110.11. Revolution Medicines, Inc. has a fifty-two week low of $34.00 and a fifty-two week high of $166.50.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period in the previous year, the firm earned ($1.13) EPS. Equities research analysts forecast that Revolution Medicines, Inc. will post -7.94 EPS for the current year.

Insider Activity

In related news, COO Margaret A. Horn sold 4,583 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the transaction, the chief operating officer owned 157,570 shares of the company’s stock, valued at approximately $15,675,063.60. This trade represents a 2.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Lin Wei sold 2,073 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $206,222.04. Following the transaction, the insider directly owned 101,366 shares of the company’s stock, valued at $10,083,889.68. The trade was a 2.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 148,592 shares of company stock worth $20,855,132 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on RVMD. Royal Bank Of Canada increased their price objective on shares of Revolution Medicines from $165.00 to $182.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Wedbush reiterated an “outperform” rating on shares of Revolution Medicines in a report on Monday, June 1st. Evercore reiterated an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Jefferies Financial Group began coverage on shares of Revolution Medicines in a report on Monday, March 16th. They issued a “buy” rating for the company. Finally, Guggenheim increased their price objective on shares of Revolution Medicines to $205.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Revolution Medicines has a consensus rating of “Buy” and a consensus price target of $123.72.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.